Dr. David Altchek, Mets medical director and Tommy John surgeon, dead at age 68
His death was announced by the Hospital for Special Surgery, where he was co-chief emeritus. Altchek told associates last year he had been diagnosed with a brain tumor.
He was the Mets head team physician from 1991-2001 and medical director from 2005-24, physician of the U.S. Davis Cup team from 1999-2003 and North American medical director of the ATP Tour. Altchek was co-chief of HSS's sports medicine and shoulder service from 2005-14.
'While Dr. Altchek's intelligence and innovations certainly benefited his patients — and sports medicine in general — his biggest impact was his warm, friendly caring personality,' said Glenn S. Fleisig, biomechanics research director of the American Sports Medicine Institute. 'Colleagues, friends, and patients all loved David and are thankful for the time we had with him.'
A son of orthopedic surgeon Martin Altchek, David attended Middletown High School in New York, received his undergraduate degree at Columbia and his medical degree from Cornell University Medical College in 1982. He interned at The New York Hospital and became a resident at HSS, where he had a fellowship under Dr. Russell Warren, HSS's surgeon in chief from 1993-03 and a longtime team physician of the New York Giants.
'My first Tommy John surgery was in 1993, and I did the procedure that Dr. Jobe, Dr. Frank Jobe prescribed,' Altchek said during a 2024 interview with The Associated Press. 'It took 2 1/2 hours and I was exhausted. And I realized then that we had to do something about Tommy John surgery. We had to make it a little bit easier.'
Working with residents and fellows, Altchek developed what was called a docking procedure and tested it on about 100 elbows.
'It worked and it worked amazingly well,' Altchek said. 'We really did not change it at all for 20-something years."
Altchek estimated last year he had performed more than 2,400 Tommy John surgeries. He was a preferred surgeon for the Tommy John procedure in recent years along with Texas Rangers physician Dr. Keith Meister and Los Angeles Dodgers head team physician Dr. Neal ElAttrache.
Part of Altchek's job was to reassure a player his baseball career was not over.
'You tell them this is unfortunate, but this is your MRI. This is probably why it happened — meaning you threw outside the envelope of your tissue quality," he explained. "But we have a procedure that can repair your ligament and reconstruct it in a kind of belt, suspenders way that once it heals the likelihood of you going back to pitching at the same level or above is 95%.'
Altchek received Columbia's John Jay Award for Distinguished Professional Achievement in 2003.
He is survived by his wife, the former Anne Salmson, whom he married in 1981, sons Charles and Christopher, and daughters Chloe and Sophie. Charles is president of Major League Soccer's third-tier MLS Next Pro minor league and was the Ivy League men's soccer player of the year while at Harvard in 2005 and 2006.
___
AP MLB: https://apnews.com/hub/mlb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Joe Flacco on Kenny Pickett's injury as quarterback race continues: 'You don't want to see something like that'
Cleveland Browns quarterback Joe Flacco spoke about the unfortunate timing of an injury to teammate Kenny Pickett in training camp on Monday. Over the weekend, the tight competition for the starting spot shifted when Pickett sustained a hamstring injury in practice. "I think, listen, I think there's worse timing," Flacco said after Monday's practice. "But at any point when you've been working so hard, you don't want to see something like that." Both Flacco and Pickett joined the Browns ahead of this NFL season and lead the depth chart ahead of rookies Dillon Gabriel and Shedeur Sanders. The Akron Beacon Journal initially reported that the second week of Browns training camp would include adjustments in the quarterback reps. Come Monday afternoon, Gabriel was filmed on the field during passing drills. With Pickett sidelined and Gabriel getting reps in, Sanders recently had an impressive showing late into the first week of training camp. ESPN's Daniel Oyefusi counted that Sanders had more scrimmage sets than Flacco throughout Week 1 of camp. Sanders was also filmed throwing touchdown passes over the defense in training. However, his reps had not come with the first-team offense. All four quarterbacks are fresh faces to the Browns locker room, apart from Flacco, who had a one-year stint with the Browns in 2023. Pickett joined Cleveland after two years with the Pittsburgh Steelers and a season with the Philadelphia Eagles. In his lone, Super Bowl-winning year with the Birds, Pickett made five appearances and completed 25 of 42 attempts for two touchdowns. Flacco's long career was mostly spent in Baltimore, where he was the signal caller for the Ravens for 11 years. He has since played for the Denver Broncos, New York Jets and Indianapolis Colts. The Browns had Deshaun Watson, Jameis Winston and Dorian Thompson-Robinson in the position just last season. They had a complete wipeout of their quarterbacks after a 3-14 season, starting with a season-ending Achilles tear for Watson in Week 7. He then re-ruptured his Achilles after rolling his ankle during the rehab process, putting his availability for 2025 in doubt. Watson's contract will count just under $36 million against the Browns' salary cap this season, per Spotrac. Despite Pickett's injury, the Browns have previously expressed they will not trade any of their quarterbacks. Cleveland will open their season on September 9 against the Cincinnati Bengals.
Yahoo
7 minutes ago
- Yahoo
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
- Company commends FDA for swift and comprehensive review of available information - Shipments to sites of care will resume imminently - Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients CAMBRIDGE, Mass., July 28, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) notified Sarepta that it may lift its voluntary pause on shipments of ELEVIDYS (delandistrogene moxeparvovec) for ambulatory patients with Duchenne. Sarepta will resume shipping ELEVIDYS to sites of care for treatment of ambulatory patients with Duchenne imminently. "Last week, at the suggestion of FDA, Sarepta made the difficult decision to pause shipments of ELEVIDYS to provide the FDA with an opportunity to complete a review of available safety information. We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of ELEVIDYS for ambulatory patients. The FDA's swift review evinces a commitment to the Duchenne population, a commitment shared by Sarepta," said Doug Ingram, chief executive officer, Sarepta. "We look forward to working collaboratively with the FDA to complete the safety label update for ELEVIDYS and to discussing the approach to risk-mitigation for non-ambulatory patients, who remain on pause pending the outcome of those discussions." FDA's review of the safety data in the ambulatory population included the case of an 8-year-old in Brazil whose death was deemed unlikely to be related to treatment with ELEVIDYS by the Brazilian health authorities. FDA's investigation has concluded the death was unrelated to treatment with ELEVIDYS and confirmed that Sarepta can resume shipments. Patients and physicians can access more information about ELEVIDYS at or by calling 1-888-727-3782. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl)ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS:Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This press release contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ongoing discussions and interactions with FDA, and ELEVIDYS, including the timing of resumed shipments to ambulatory patients. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; results from pre-clinical and early‑stage clinical trials may not be indicative of safety or efficacy in late‑stage clinical trials, and pre-clinical and clinical trials may fail to demonstrate acceptable levels of safety, efficacy, and quality of our product candidates, which could prevent or significantly delay their regulatory approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc. View source version on Contacts Investor: Ian Estepan617-274-4052iestepan@ Media: Tracy Sorrentino617-301-8566tsorrentino@ Kara Hoeger617-710-3898KHoeger@
Yahoo
7 minutes ago
- Yahoo
Cubs agree to contract extension with president of baseball operations Jed Hoyer
CHICAGO (AP) — The Chicago Cubs locked in president of baseball operations Jed Hoyer for the long term, agreeing to a multiyear contract extension on Monday. The 51-year-old Hoyer's contract was set to expire at the end of the season — his 14th with the Cubs. He was hired as general manager in 2011 and replaced Theo Epstein as president of baseball operations in 2020. The announcement came hours before Chicago opened an important three-game series at NL Central rival Milwaukee. Led by All-Stars Pete Crow-Armstrong and Kyle Tucker, the Cubs were tied with the Brewers with a league-best 62-43 record. In a statement, Hoyer said he's 'so grateful' for the 'trust and support' of the Ricketts family owners and called the Cubs 'a special organization with an amazing fan base.' "I'm excited to keep building on the momentum we have and to work with a terrific baseball operations staff to consistently deliver a championship-caliber team for this great city,' he said. Chairman Tom Ricketts praised Hoyer and his staff for building 'a healthy player development organization' and putting 'an exciting, playoff contending team on the field.' "We are looking forward to the rest of the season and to working with Jed for years to come,' he added. ___ AP MLB:
